Molly Harper - 12 Dec 2025 Form 4 Insider Report for CATALYST PHARMACEUTICALS, INC. (CPRX)

Role
Director
Signature
/s/ Molly Harper
Issuer symbol
CPRX
Transactions as of
12 Dec 2025
Net transactions value
-$506,320
Form type
4
Filing time
16 Dec 2025, 17:00:29 UTC
Previous filing
10 Dec 2025
Next filing
30 Dec 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Harper Molly Director 355 ALHAMBRA CIRCLE, SUITE 801, CORAL GABLES /s/ Molly Harper 16 Dec 2025 0001871470

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CPRX Common stock, par value $0.001 per share Options Exercise $115,600 +20,000 +220% $5.78 29,106 12 Dec 2025 Direct
transaction CPRX Common stock, par value $0.001 per share Sale $360,195 -15,527 -53% $23.20 13,579 12 Dec 2025 Direct F1, F2
transaction CPRX Common stock, par value $0.001 per share Sale $106,162 -4,473 -33% $23.73 9,106 12 Dec 2025 Direct F1, F3
transaction CPRX Common stock, par value $0.001 per share Sale $155,563 -6,746 -74% $23.06 2,360 12 Dec 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CPRX Options to purchase common stock Options Exercise $0 -20,000 -13% $0.000000 128,497 12 Dec 2025 Common Stock 20,000 $5.78 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares were sold on the open market for personal reasons and to fund the exercise price of the stock options, and not as a result of any disagreement with the Company.
F2 Represents a weighted average price for the shares sold. Shares were sold in a range between $22.67 and $23.67 per share.
F3 Represents a weighted average price for the shares sold. Shares were sold in a range between $23.67 and $23.82 per share.
F4 Options vested in three annual tranches beginning on June 29, 2022.